

Product datasheet for TL306995V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

METTL9 Human shRNA Lentiviral Particle (Locus ID 51108)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: METTL9 Human shRNA Lentiviral Particle (Locus ID 51108)

Locus ID: 51108

Synonyms: CGI-81; DREV; DREV1; PAP1

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: METTL9 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001077180, NM 001288659, NM 001288660, NM 016025, NM 016025.1, NM 016025.2,

NM 016025.3, NM 016025.4, NM 001077180.1, NM 001077180.2, NM 001288660.1,

NM 001288659.1, BC000195, BC000195.1, BM149762, NM 016025.5

UniProt ID: Q9H1A3

Summary: Protein-histidine N-methyltransferase that specifically catalyzes 1-methylhistidine (pros-

methylhistidine) methylation of target proteins (PubMed:33563959). Mediates methylation of

proteins with a His-x-His (HxH) motif (where 'x' is preferably a small amino acid)

(PubMed:33563959). Catalyzes methylation of target proteins such as S100A9, NDUFB3, SLC39A5, SLC39A7, ARMC6 and DNAJB12; 1-methylhistidine modification may affect the binding of zinc and other metals to its target proteins (PubMed:33563959). Constitutes the main methyltransferase for the 1-methylhistidine modification in cell (PubMed:33563959).

[UniProtKB/Swiss-Prot Function]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





METTL9 Human shRNA Lentiviral Particle (Locus ID 51108) - TL306995V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).